Sana Biotechnology (SANA) Other Non-Current Liabilities (2020 - 2026)

Sana Biotechnology has reported Other Non-Current Liabilities for 7 years, with the latest figure at $83.2 million in Q1 2026.

• Quarterly Other Non-Current Liabilities rose 781.08% year-over-year to $83.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $83.2 million (up 781.08% YoY) and the FY2025 annual result came in at $10.6 million, up 7.11% from the prior year.
• Other Non-Current Liabilities grew to $83.2 million in Q1 2026 per SANA's latest filing, from $10.6 million in the prior quarter.
• Over five years, Other Non-Current Liabilities peaked at $109.6 million in Q4 2023 and troughed at $7.5 million in Q3 2024.
• A 5-year average of $62.3 million and a median of $65.9 million in 2025 frame the typical range for Other Non-Current Liabilities.
• The sharpest annual moves came in 2024 and 2026: Other Non-Current Liabilities slumped 90.97% in 2024, then soared 781.08% in 2026.
• Over 5 years, Other Non-Current Liabilities stood at $95.0 million in 2022, then gained by 15.33% to $109.6 million in 2023, then plunged by 90.97% to $9.9 million in 2024, then grew by 7.11% to $10.6 million in 2025, then soared by 684.91% to $83.2 million in 2026.
• According to Business Quant data, Other Non-Current Liabilities over the past three periods registered $83.2 million, $10.6 million, and $7.9 million for Q1 2026, Q4 2025, and Q3 2025 respectively.